SCHEMBL4531446

SCHEMBL4531446

CC(C)(C)c1cccc(OC(C(=O)NO)c2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.45
FFAR1 O14842 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC3 O15379 3/20 0.41
HDAC8 Q9BY41 3/20 0.41
HDAC6 Q9UBN7 3/20 0.41
HDAC4 P56524 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC7 Q8WUI4 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC10 Q969S8 2/20 0.41
HDAC11 Q96DB2 2/20 0.41
HDAC9 Q9UKV0 2/20 0.41
HDAC5 Q9UQL6 2/20 0.41
BCHE P06276 2/20 0.41
GCGR P47871 3/20 0.41
ADCY6 O43306 1/20 0.41
ADCY3 O60266 1/20 0.41
ADCY9 O60503 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13789836 0.86 PPARG (0.61) PPARGMEN1KMT2ASLC22A12
SCHEMBL4532941 0.86 GCGR (0.52) MEN1KMT2AHDAC3HDAC8HDAC6
SCHEMBL2844450 0.82 HDAC7 (0.55) KMT2AHDAC3HDAC8HDAC6HDAC4
SCHEMBL4529400 0.82 TSHR (0.50) MEN1KMT2AF10
SCHEMBL4533806 0.82 PTGS1 (0.47) MEN1KMT2AHDAC3HDAC8HDAC6
SCHEMBL4536431 0.82 OPRM1 (0.46) MEN1KMT2AHDAC3HDAC8HDAC6
SCHEMBL4529074 0.80 HDAC8 (0.46) HDAC3HDAC8HDAC6HDAC4HDAC1
SCHEMBL4534212 0.79 OGG1 (0.50) PPARGKMT2AHDAC3HDAC8HDAC6
SCHEMBL4532634 0.79 HDAC4 (0.56) PPARGMEN1KMT2AHDAC3HDAC8
SCHEMBL4540076 0.78 BCHE (0.51) MEN1KMT2AHDAC3HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 PPARG 1729/4885FFAR1 2662/4885MEN1 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.